INS and Parkinson disease: .Given the correlation between PD and glucose metabolism disorders and energy conversion disorders, researchers have increasingly focused on the neuroprotective effects of GLP-1.GLP-1 receptor agonists provide neuroprotection through multiple pathways, including improving insulin sensitivity, reducing oxidative stress, and enhancing mitochondrial function, as shown in Figure 2.